GenMark Diagnostics (GNMK) Upgraded by Zacks Investment Research to Hold
Zacks Investment Research upgraded shares of GenMark Diagnostics (NASDAQ:GNMK) from a sell rating to a hold rating in a report released on Wednesday.
According to Zacks, “GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor® XT-8 system is the second generation in GenMark Dx’s eSensor® platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual’s ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual’s increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California. “
A number of other analysts have also commented on GNMK. Canaccord Genuity reissued a buy rating and set a $14.00 price target (down from $17.00) on shares of GenMark Diagnostics in a research note on Monday, August 7th. Cowen reissued an outperform rating and set a $17.00 price target on shares of GenMark Diagnostics in a research note on Wednesday, August 2nd. BidaskClub lowered GenMark Diagnostics from a hold rating to a sell rating in a research note on Monday, August 14th. Needham & Company LLC reissued a buy rating and set a $15.00 price target (down from $17.00) on shares of GenMark Diagnostics in a research note on Wednesday, September 13th. Finally, BTIG Research reissued a buy rating and set a $13.00 price target on shares of GenMark Diagnostics in a research note on Thursday, August 31st. One analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $11.80.
GenMark Diagnostics (NASDAQ:GNMK) last released its quarterly earnings data on Thursday, November 2nd. The medical equipment provider reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The business had revenue of $11.60 million during the quarter, compared to analyst estimates of $14.56 million. GenMark Diagnostics had a negative net margin of 116.76% and a negative return on equity of 100.33%. The business’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period last year, the business earned ($0.27) earnings per share. equities research analysts predict that GenMark Diagnostics will post -1.17 EPS for the current year.
In related news, SVP Eric Stier sold 2,750 shares of GenMark Diagnostics stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $9.60, for a total value of $26,400.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Hany Massarany sold 8,252 shares of GenMark Diagnostics stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $4.74, for a total value of $39,114.48. Following the completion of the transaction, the insider now directly owns 362,957 shares in the company, valued at $1,720,416.18. The disclosure for this sale can be found here. Insiders have sold 59,650 shares of company stock worth $471,189 over the last three months. Insiders own 7.50% of the company’s stock.
Several institutional investors have recently bought and sold shares of GNMK. BlueCrest Capital Management Ltd acquired a new position in shares of GenMark Diagnostics in the second quarter worth approximately $126,000. Legal & General Group Plc lifted its stake in shares of GenMark Diagnostics by 2.1% in the second quarter. Legal & General Group Plc now owns 11,521 shares of the medical equipment provider’s stock worth $137,000 after acquiring an additional 240 shares during the period. Susquehanna International Group LLP acquired a new position in shares of GenMark Diagnostics in the second quarter worth approximately $137,000. Quantitative Systematic Strategies LLC lifted its stake in shares of GenMark Diagnostics by 18.4% in the second quarter. Quantitative Systematic Strategies LLC now owns 13,147 shares of the medical equipment provider’s stock worth $159,000 after acquiring an additional 2,047 shares during the period. Finally, Wrapmanager Inc. acquired a new position in shares of GenMark Diagnostics in the third quarter worth approximately $172,000.
ILLEGAL ACTIVITY NOTICE: “GenMark Diagnostics (GNMK) Upgraded by Zacks Investment Research to Hold” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/03/genmark-diagnostics-gnmk-upgraded-by-zacks-investment-research-to-hold.html.
About GenMark Diagnostics
GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for GenMark Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc and related stocks with our FREE daily email newsletter.